Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Overview 6 Therapeutics Development 7 Pipeline Products for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview 7 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics under Development by Companies 8 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Products under Development by Companies 11 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development 12 AFFiRiS AG 12 AstraZeneca Plc 13 Corestem Inc 14 MitoDys Therapeutics Ltd 15 Modag GmbH 16 Neuropore Therapies Inc 17 Prana Biotechnology Ltd 18 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Anle-138b - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 AZD-3241 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CS-10BR05 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 NPT-20011 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 PBT-434 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 PD-01 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 PD-03 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules for Neurodegenerative Disease - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40

List of Tables Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by AFFiRiS AG, H2 2016 12 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by AstraZeneca Plc, H2 2016 13 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H2 2016 14 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by MitoDys Therapeutics Ltd, H2 2016 15 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Modag GmbH, H2 2016 16 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H2 2016 17 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Prana Biotechnology Ltd, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 List of Figures Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 10 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Targets, H2 2016 20 Number of Products by Stage and Targets, H2 2016 20 Number of Products by Mechanism of Actions, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 22 Number of Products by Routes of Administration, H2 2016 24 Number of Products by Stage and Routes of Administration, H2 2016 24 Number of Products by Molecule Types, H2 2016 26 Number of Products by Stage and Molecule Types, H2 2016 26

AFFiRiS AG AstraZeneca Plc Corestem Inc MitoDys Therapeutics Ltd Modag GmbH Neuropore Therapies Inc Prana Biotechnology Ltd